The “Get Moving Trial”: A phase I/II RCT of home-based (P)rehabilitation ((P)REHAB) with ExerciseRx in muscle-invasive bladder cancer (MIBC)—Study protocol for a randomized controlled trial. New phase ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...
TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...
rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...
Phase 1/2 INTerpath-005 study: V940 (mRNA-4157) plus pembrolizumab with or without enfortumab vedotin (EV) for resected high-risk muscle-invasive urothelial carcinoma (MIUC). This is an ASCO Meeting ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
Credit: Ferring. Adstiladrin is a novel nonreplicating adenoviral vector-based gene therapy that delivers a copy of a gene encoding a human interferon-alfa 2b to the bladder urothelium. Adstiladrin ® ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results